

12 Oct 2022



# **CMBI Credit Commentary**

# Fixed Income Daily Market Update 固定收益部市场日报

- Markets were overall weak this morning. HAOHUA/SINOCH widened 20-30bps due to U.S. sanction while we saw onshore buying interests to it when the yields close to 6%.
- Asian AT1s Part I: Our picks on Chinese G-SIBs AT1s, buy BCHINA 3.6 PERP and ICBCAS 3.58 PERP. See below.
- **RISSUN**: Consent solicitation to waive defaults in interest payments of two USD bonds for half year. RISSUNs down c0.25pt this morning. See below.
- ❖ Trading desk comments 交易台市场观点

Yesterday, China IG space resonated with global markets to show a risk-off tone amid RM aggressively selling, on both recession concerns and geopolitical risks. TMTs notably underperformed to close 5-10bps wider, along with stocks plunged amid escalating US-China tech race. TENCNT/ BABA/TAISEM were marked 8-10bps wider, driven by FM selling. Financials space performed relatively resilient. AT1s had more two-ways. BCHINA/ IABCAS AT1s slightly drifted 0.125-0.25pt lower. CHOHIN 5.7 Perp/ NANYAN 6.5 Perp emerged better selling interests. T2 benchmarks CCB/ BOCOHK opened 2-5bps tighter in the AM session but widened 2-5bps amid the sell-off in China space on the day. IG property benchmarks were dragged further down 1-3pts, in line with HYs plunging on the recent CIFI woes. VNKRLEs/LNGFORs/SINOCEs down 2-3pts. China HYs tested new lows with CBIC-backed peers also been questioned. Market eyed CIFIHG'23 slumped another 10.5pts while rest of the curve dropped 3.5-5.5pts, amid CB holders had yet to receive coupon on HKD2.55bn 6.95% CBs by EOD. CIFIHGs were traded at low-teens, as CIFI group was also in the negotiation to defer amortization of USD70mn to month-end on a HSBC-led syndicated loan. COGARDs down 3.5-5pts on contagion effect. CHINSC 23-24s were down another 6.5-9.5pts, following the missed payments news with Shimao yesterday. Elsewhere, RISSUN'24 was down 5pts. Non-property space also trended lower. In industrial space, FOSUNIs were quoted down 1.5-2.5pts HONGQI/ANTOIL were unchanged. MPELs/WYNMACs ended down 2-4pts. Away from China, India HYs were relatively firm with VEDLNs closed 1.5-2.5pts higher. Indonesian HY MEDCIJs were up 0.5-3.5pts, amid the oil and gas producer Medco announced buyback boost options for deleveraging.

Flows remained better selling in LGFV/SOE Perp spaces, driven by non-Chinese AM continuing to offload LGFV positions, i.e. mostly high coupon/high yielding seasoned issues across the yield curve. We saw NBRM selling CNBG and SINOCH Perps in light of street-driven selloff in HAOHUA curve,

Glenn Ko, CFA 高志和 (852) 3657 6235 glennko@cmbi.com.hk

**Cyrena Ng, CPA** 吳蒨瑩 (852) 3900 0801 cyrenang@cmbi.com.hk

Jerry Wang 王世超 (852) 3761 8919 jerrywang@cmbi.com.hk as talks of sanction fear resurfaced after the company got on the US DoD list again. Overall the SOE space drifted 10-40bps wider on RM selling. HAOHUA widened 30-40bps and SINOCH were also 10-20bps wider amid street selling, to reflect the mounting market concerns on US. As dealers hit the street after market digged out that the US unverified list enclosed ChinaChem on last Wednesday (5<sup>th</sup> Oct), SINOPE/CNOOC widened 5-15bps with RM and PB selling. In general, flows on Chemical papers were still more supportive, as compared to the overall China credit especially properties. We saw the SOE Perps/AT1s taking pressure but still well digested, as AT1 Strong names like ICBCAS 3.2 PERP/ CCB 2.85' 32 were supported by short covering buying following despite higher UST yields. In LGFV space, ZZCITY'25/CQNANA'26 remained better selling.

## Last trading day's Top Movers

Top Performers	Price	Change
MEDCIJ 6 3/4 01/30/25	95.7	3.6
VEDLN 6 1/8 08/09/24	64.5	2.4
HRINTH Float 02/24/25	88.4	1.9
VEDLN 9 1/4 04/23/26	61.2	1.8
HSBC Float PERP	72.4	0.9

Top Underperformers	Price	Change
CIFIHG 5 1/2 01/23/23	13.5	-10.3
CHINSC 7 1/4 04/19/23	18.0	-9.5
CHINSC 7 3/8 04/09/24	15.2	-6.5
CIFIHG 6.55 03/28/24	10.8	-5.6
FIHUCN 5 02/26/28	84.4	-5.0

#### Macro News Recap 宏观新闻回顾

**Macro** – U.S. stock markets were overall weak on Tuesday. The S&P (-0.65%), Dow (+0.12%) and Nasdaq (-1.10%) were divergent and markets are waiting for September CPI, which is expected to slightly down by month. The PBOC published 9M22 financial data that new bank loans and total social financing are higher than expectation. New bank loans was RMB2.47tn, increasing RMB810.8bn yoy. Total social financing increased RMB3.53tn, growing RMB624.5bn yoy. The U.S. treasury yields kept ascending yesterday and the 2/5/10/30 yields bear steepened to 4.30%/4.14%/3.93%/3.92%, respectively.

# ❖ Desk analyst comments 分析员市场观点

#### Asian AT1s Part I – Our picks on Chinese G-SIBs AT1s

In Part I of our Asia AT1s comments, we focus our discussions on China AT1 and our rationale on why we believe that China AT1s, especially those of China G-SIBs, offer more predictable return.

To start with, the return predictability of AT1s are subject to 1) likelihood of loss absorption; 2) likelihood of cancellation of non-cumulative distribution; and 3) likelihood of being called, especially on the first call dates.

So far, there is no precedent on the principal of the AT1s of Chinese G-SIBs being written down or converted into equity. There is also no precedent for Chinese G-SIBs to cancel distribution, and all of the Chinese AT1s were called on their respective first call dates. Please see Table 1 for examples of loss absorption or non-call of European AT1s.

While AT1s in Europe offer better YTC, we would argue that Asian AT1s, especially Chinese G-SIBs' AT1s, offer more predictable return because of their lower likelihood of loss absorption, higher certainty of being called on the first call dates and scheduled distributions.

Amongst China G-SIBs' AT1s, our picks are **BCHINA 3.6 PERP** (callable Mar'25) and **ICBCAS 3.58 PERP** (callable Sep'25) in view of their higher YTC, relatively shorter-tenor and better trading liquidity. These AT1s also offer decent yield pick-up (81-98bps) over their senior bonds.




Chart 1: Selected China G-SIBs' AT1 YTC

Click here for full report

## > RISSUN: Consent solicitation to waive defaults in interest payments for half year

RiseSun launched consent solicitation to waive defaults in interest payments of its two offshore bonds: RISSUN 9.5 03/16/23 (o/s USD199.3mn) and RISSUN 9.5 09/17/24 (o/s USD531.3mn) of which the interest should be paid in 16 Sep'22 and 17 Sep'22 originally. Though there is 30 days grace period for both bonds' missed payment, the company estimates it will have no enough resources to pay it before 16/17 Oct. The company proposed 0.25pt consent fee to waive the non-payment default for half year, see below for details:

Date	Bond	Consent fee	Details
11/10/2022	RISSUN 9.5 03/16/23 RISSUN 9.5 09/17/24	0.25pt	-Waive the interest payment default of: RISSUN 9.5 03/16/23 until 03/16/23 RISSUN 9.5 09/17/24 until 03/17/23 -Consent fee payment date: 28 Oct'22 in cash -Minimum acceptance level: 75% -Expiration deadline: 25 Oct'22

### Offshore Asia New Issues (Priced)

Issuer/Guarantor	Size (USD mn)	Tenor	Coupon	Yield	Issue Rating (M/S/F)
Oriental Capital Company Limited	USD164	3yr	7.0%	7.0%	-/-/-

### Offshore Asia New Issues (Pipeline)

Issuer/Guarantor	Currency	Size (USD mn)	Tenor	IPG	Issue Rating (M/S/F)
Syngenta Group Co., Ltd.	USD	-	3.5yr	T+125	Baa1/BBB+/A

#### Market conditions and color

- Regarding onshore primary issuances, there were 81 credit bonds issued yesterday with an amount of RMB75bn. As for Month-to-date, 142 credit bonds were issued with a total amount of RMB152bn raised, representing a 41.5% yoy increase
- **[BJHKWY]** Beijing Hongkun Weiye Real Estate announced it cannot pay interest and principal of 18Hongkun01 (o/s RMB100mn)
- **[BUMIIJ]** Bumi Resources plans to launch its 200bn shares (up to cUSD1.6bn) private placement on 18 Oct, Mach Energy (Hong Kong) will subscribe 170bn shares and Treasure Global Investments will subscribes 30bn shares; The company's unit Eterna announced to redeem all Series B notes (o/s USD22.38mn)
- [EVERRE] Moody's withdrawn Evergrande and its subsidiaries' ratings due to insufficient information
- **[KAISAG]** Moody's withdrawn Kaisa's ratings due to insufficient information
- [LNGFOR] Longfor Group acquires four land parcels located in tier1/2 cities for RMB5.71bn in September
- **[MEDCIJ]** Medco launched tender offer to purchase for cash up to USD250mn in the aggregate purchase price of MEDCIJ 6.75 01/30/2025 (o/s USD500mn), MEDCIJ 7.375 05/14/2026 (o/s USD540.8mn) and MEDCIJ 6.375 01/30/2027 (o/s USD601.7mn)
- [SUNKWP] Sunkwan Properties extended expiration deadline in relation to consent solicitation for SUNKWP 12.25 07/17/23 to 17 October

CMB International Global Markets Limited Fixed Income Department
Tel: 852 3761 8867/852 3657 6291
fis @cmbi.com.hk

#### **Author Certification**

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## **Important Disclosures**

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

Disclaimer:

CMBIGM or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc..,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report

# 12 Oct 2022

is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.